SCHEMBL17845381

SCHEMBL17845381

CC1(NS(=O)(=O)c2ccc([N+](=O)[O-])c(Nc3ccccc3)c2)CC1

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PARG Q86W56 9/20 0.50
TDP1 Q9NUW8 2/20 0.49
MAPT P10636 2/20 0.49
POLB P06746 1/20 0.49
L3MBTL1 Q9Y468 3/20 0.49
ALDH1A1 P00352 1/20 0.49
MAPK1 P28482 1/20 0.49
CASP7 P55210 1/20 0.49
WNK1 Q9H4A3 1/20 0.46
ALDH3A1 P30838 3/20 0.44
LMNA P02545 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
PKM P14618 1/20 0.42
HCAR3 P49019 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17825245 0.84 PARG (0.49) PARGMAPTPOLBALDH1A1KMT2A
SCHEMBL31122016 0.83 PARG (0.54) PARG
SCHEMBL17845691 0.83 PARG (0.54) PARG
SCHEMBL17845307 0.78 PARG (0.48) PARG
SCHEMBL31121984 0.78 PARG (0.47) PARG
SCHEMBL17845472 0.78 PARG (0.47) PARG
SCHEMBL31121959 0.78 PARG (0.48) PARG
SCHEMBL17863667 0.77 PARG (0.42) PARGMEN1KMT2A
SCHEMBL20365046 0.77 PARG (0.48) PARG
SCHEMBL17825135 0.77 PARG (0.50) PARGTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250223266-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2025-07-10 US disclosed
US-12129236-B2 PARG inhibitory compounds CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2024-10-29 US disclosed
CN-112979631-B PARG inhibiting compounds 癌症研究科技有限公司 2024-09-20 CN disclosed
US-20210380539-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2021-12-09 US disclosed
US-20210380539-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2021-12-09 US disclosed
EP-3907224-A1 PARG INHIBITORY COMPOUNDS Cancer Research Technology Limited (GB) 2021-11-10 EP disclosed
EP-3233845-B1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECH LTD (GB) 2021-07-21 EP disclosed
CN-112979631-A PARG inhibiting compounds 癌症研究科技有限公司 2021-06-18 CN disclosed
US-10995073-B2 PARG inhibitory compounds CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2021-05-04 US disclosed
US-10995073-B2 PARG inhibitory compounds CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2021-05-04 US disclosed
CN-107295799-B PARG inhibiting compounds 癌症研究科技有限公司 2021-03-16 CN disclosed
US-20200165208-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2020-05-28 US disclosed
US-20200165208-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2020-05-28 US disclosed
US-20180194738-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2018-07-12 US disclosed
US-20180194738-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2018-07-12 US disclosed
US-20180194738-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2018-07-12 US disclosed
EP-3233845-A1 PARG INHIBITORY COMPOUNDS Cancer Research Technology Limited (GB) 2017-10-25 EP disclosed
WO-2016097749-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2016-06-23 WO disclosed
WO-2016097749-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2016-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210380539-A1 PARG INHIBITORY COMPOUNDS PARP11, PARG, PARP16 PARG 2/4885TDP1 233/4885MAPT 3262/4885
US-20180194738-A1 PARG INHIBITORY COMPOUNDS PARG, PARP11, PARP16 PARG 1/4885TDP1 223/4885MAPT 3085/4885
US-10995073-B2 PARG inhibitory compounds PARG, PARP11, PARP16 PARG 1/4885TDP1 223/4885MAPT 3085/4885
US-12129236-B2 PARG inhibitory compounds PARP11, PARG, PARP16 PARG 2/4885TDP1 233/4885MAPT 3262/4885
US-20200165208-A1 PARG INHIBITORY COMPOUNDS PARG, PARP11, PARP16 PARG 1/4885TDP1 223/4885MAPT 3085/4885
US-20250223266-A1 PARG INHIBITORY COMPOUNDS PARG, PARP11, PARP16 PARG 1/4885TDP1 223/4885MAPT 3085/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.